Nanologica AB (OSTO:NICA) Cyclically Adjusted Revenue per Share: kr0.46 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NICA Nanologica AB OSTO:NICA
46 GF Score
Price kr0.44
GF Value kr4.27
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Nanologica AB Cyclically Adjusted Revenue per Share?

Nanologica AB OSTO:NICA -2.84% 46 Cyclically Adjusted Revenue per Share is kr0.46 as of Mar. 2026. GuruFocus rates OSTO:NICA with a GF Score™ of 46/100 and a GF Value™ of kr4.27 (Possible Value Trap). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nanologica AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.237. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nanologica AB's average Cyclically Adjusted Revenue Growth Rate was -8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-02), Nanologica AB's current stock price is kr0.444. Nanologica AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr0.46. Nanologica AB's Cyclically Adjusted PS Ratio of today is 0.97.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Nanologica AB was 4.35. The lowest was 0.78. And the median was 2.38.


Nanologica AB  (OSTO:NICA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nanologica AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.444/0.46
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Nanologica AB was 4.35. The lowest was 0.78. And the median was 2.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nanologica AB Cyclically Adjusted Revenue per Share Related Terms


Nanologica AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Cyclically Adjusted Revenue per Share Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.56 0.45

Nanologica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.48 0.47 0.45 0.46

OSTO:NICA vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Nanologica AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nanologica AB's Cyclically Adjusted PS Ratio falls into.


OSTO:NICA
46GF Score
Nanologica AB OSTO:NICA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanologica AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.237/133.5600*133.5600
=0.237

Current CPI (Mar. 2026) = 133.5600.

Nanologica AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.012 101.019 0.016
201609 0.120 101.138 0.158
201612 0.300 102.022 0.393
201703 0.002 102.022 0.003
201706 0.000 102.752 0.000
201709 0.039 103.279 0.050
201712 0.475 103.793 0.611
201803 0.086 103.962 0.110
201806 0.029 104.875 0.037
201809 0.061 105.679 0.077
201812 0.130 105.912 0.164
201903 0.129 105.886 0.163
201906 0.169 106.742 0.211
201909 0.114 107.214 0.142
201912 0.113 107.766 0.140
202003 0.208 106.563 0.261
202006 0.174 107.498 0.216
202009 0.071 107.635 0.088
202012 0.208 108.296 0.257
202103 0.192 108.360 0.237
202106 0.153 108.928 0.188
202109 0.071 110.338 0.086
202112 0.023 112.486 0.027
202203 0.009 114.825 0.010
202206 0.007 118.384 0.008
202209 0.013 122.296 0.014
202212 0.018 126.365 0.019
202303 0.009 127.042 0.009
202306 0.018 129.407 0.019
202309 0.009 130.224 0.009
202312 0.002 131.912 0.002
202403 0.134 132.205 0.135
202406 0.047 132.716 0.047
202409 0.014 132.304 0.014
202412 0.090 132.987 0.090
202503 0.145 132.825 0.146
202506 0.026 133.699 0.026
202509 0.032 133.480 0.032
202512 0.058 133.390 0.058
202603 0.237 133.560 0.237

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.46 mean?
Nanologica AB (OSTO:NICA) has a Cyclically Adjusted Revenue per Share of kr0.46 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nanologica AB and its competitors.
Is Nanologica AB's Cyclically Adjusted Revenue per Share too high?
Nanologica AB's current Cyclically Adjusted Revenue per Share is kr0.46. Overall, Nanologica AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Nanologica AB's Cyclically Adjusted Revenue per Share of kr0.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nanologica AB and its competitors. Nanologica AB's current Cyclically Adjusted Revenue per Share is kr0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.27, compared to a current price of kr0.44 — trading 89.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.46. Nanologica AB's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Cyclically Adjusted Revenue per Share is kr0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanologica AB (OSTO:NICA) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of kr0.44 is trading 89.6% below its estimated GF Value™ of kr4.27. GuruFocus considers Nanologica AB to be Possible Value Trap.

Key valuation signals for OSTO:NICA:

  • Cyclically Adjusted Revenue per Share: kr0.46
  • GF Value™: kr4.27 vs. price of kr0.44 (89.6% below fair value)
  • GF Score™: 46/100 with 9 warning signs

No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanologica AB Business Description

Other Exchanges 4YD:Germany
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score

Get the complete analysis for OSTO:NICA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.44
Price
kr4.27
GF Value